Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.

Weng J, Tao Y, Xu Z, Zhou S, Xiao D, Zhu Z, Zheng R, Yang Y, Chen Y

Journal of evidence-based medicine10 Jun 2024Cited by 2 (Europe PMC)

PMID38858300DOI10.1111/jebm.12620PepBankPUB-38858300

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with uncontrolled type 2 diabetes, free combination of basal insulin and a GLP-1RA gave HbA1c control comparable to a fixed-ratio combination (mean difference 0.07%).
In plain wordsIn adults with type 2 diabetes, separate insulin and GLP-1 drug controlled HbA1c about as well as a fixed-ratio product.
Peptide
Liraglutide
Outcome
No significant changeHbA1c control, free combination versus FRC
Study
n: not reported in source
Comparator
Fixed-ratio combination (FRC)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
MD
0.07%
free combination vs FRC
Source sentences
Summary
The forest plots revealed comparable HbA1c control (mean difference (MD) = 0.07%, 95% confidence interval (CI): -0.17 to -0.30) between free combination and FRC.
1 context sentence(design, population, supporting numbers)
Summary · context
Phase III clinical trials involving FRC or free combination in patients with uncontrolled T2DM were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3885830001
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with uncontrolled type 2 diabetes, body weight differed significantly between free combination of basal insulin and a GLP-1RA and a fixed-ratio combination (mean difference -2.06 kg).
In plain wordsIn adults with type 2 diabetes, body weight differed between separate insulin plus GLP-1 drug and a fixed-ratio product.
Peptide
Liraglutide
Outcome
Direction not reportedBody weight, free combination versus FRC
Study
n: not reported in source
Comparator
Fixed-ratio combination (FRC)
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
MD
−2.06 kg
free combination vs FRC
Source sentences
Summary
However, there were significant differences in the body weight (MD = -2.06 kg; 95% CI: -3.34 to -0.77), SBP (MD = -1.22 mmHg; 95% CI: -2.41 to -0.04), and DBP (MD = -1.09 mmHg; 95% CI: -1.94 to -0.24) between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Phase III clinical trials involving FRC or free combination in patients with uncontrolled T2DM were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3885830002
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with uncontrolled type 2 diabetes, systolic blood pressure differed significantly between free combination of basal insulin and a GLP-1RA and a fixed-ratio combination (mean difference -1.22 mmHg).
In plain wordsIn adults with type 2 diabetes, systolic blood pressure differed slightly between separate insulin plus GLP-1 drug and a fixed-ratio product.
Peptide
Liraglutide
Outcome
Direction not reportedSystolic blood pressure, free combination versus FRC
Study
n: not reported in source
Comparator
Fixed-ratio combination (FRC)
Analysis
Secondary
Outcome group
Blood pressure · Cardiovascular
Measurements
MD
−1.22 mmHg
free combination vs FRC
Source sentences
Summary
However, there were significant differences in the body weight (MD = -2.06 kg; 95% CI: -3.34 to -0.77), SBP (MD = -1.22 mmHg; 95% CI: -2.41 to -0.04), and DBP (MD = -1.09 mmHg; 95% CI: -1.94 to -0.24) between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Phase III clinical trials involving FRC or free combination in patients with uncontrolled T2DM were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3885830003
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with uncontrolled type 2 diabetes, diastolic blood pressure differed significantly between free combination of basal insulin and a GLP-1RA and a fixed-ratio combination (mean difference -1.09 mmHg).
In plain wordsIn adults with type 2 diabetes, diastolic blood pressure differed slightly between separate insulin plus GLP-1 drug and a fixed-ratio product.
Peptide
Liraglutide
Outcome
Direction not reportedDiastolic blood pressure, free combination versus FRC
Study
n: not reported in source
Comparator
Fixed-ratio combination (FRC)
Analysis
Secondary
Outcome group
Blood pressure · Cardiovascular
Measurements
MD
−1.09 mmHg
free combination vs FRC
Source sentences
Summary
However, there were significant differences in the body weight (MD = -2.06 kg; 95% CI: -3.34 to -0.77), SBP (MD = -1.22 mmHg; 95% CI: -2.41 to -0.04), and DBP (MD = -1.09 mmHg; 95% CI: -1.94 to -0.24) between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Phase III clinical trials involving FRC or free combination in patients with uncontrolled T2DM were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3885830004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.